mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.

BioRxiv : the Preprint Server for Biology
Kai WuDarin Edwards


Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide. The Moderna mRNA-1273 vaccine has demonstrated ~94% efficacy in a Phase 3 study and has been approved under Emergency Use Authorization. The emergence of SARS-CoV-2 variants with mutations in the spike protein, most recently circulating isolates from the United Kingdom (B.1.1.7) and Republic of South Africa (B.1.351), has led to lower neutralization from convalescent serum by pseudovirus neutralization (PsVN) assays and resistance to certain monoclonal antibodies. Here, using two orthogonal VSV and lentivirus PsVN assays expressing spike variants of 20E (EU1), 20A.EU2, D614G-N439, mink cluster 5, B.1.1.7, and B.1.351 variants, we assessed the neutralizing capacity of sera from human subjects or non-human primates (NHPs) that received mRNA-1273. No significant impact on neutralization against the B.1.1.7 variant was detected in either case, however reduced neutralization was measured against the mutations present in B.1.351. Geometric mean titer (GMT) of human sera from clinical trial participants in VSV PsVN assay using D614G spike was 1/1852. VSV pseudoviruses with s...Continue Reading


Jan 28, 2021·BMJ : British Medical Journal·Janice Hopkins Tanne
Jan 29, 2021·JAMA : the Journal of the American Medical Association·John P Moore, Paul A Offit
Feb 12, 2021·JAMA : the Journal of the American Medical Association·John MascolaAnthony S Fauci
Mar 9, 2021·Annals of Internal Medicine·A David PaltielPaul E Sax
Feb 11, 2021·Nature·Zijun WangMichel C Nussenzweig
Mar 11, 2021·Science·Katrina A LythgoeTanya Golubchik
Feb 18, 2021·Genome Génome / Conseil National De Recherches Canada·Bin Wang
Mar 17, 2021·Wiener klinische Wochenschrift·Franz X Heinz, Karin Stiasny
Mar 20, 2021·Emerging Microbes & Infections·Federica NovazziFabrizio Maggi
Mar 27, 2021·Nature Medicine·Delphine PlanasOlivier Schwartz
Mar 12, 2021·Nature·Dami A CollierRavindra K Gupta
Apr 5, 2021·Frontiers in Immunology·Jaime Fergie, Amit Srivastava
Apr 14, 2021·Expert Review of Vaccines·Lianlian BianZhenglun Liang
Mar 9, 2021·Nature·Pengfei WangDavid D Ho
Apr 27, 2021·Expert Review of Vaccines·Md Kamal HossainVasso Apostolopoulos
Apr 29, 2021·The Journal of Experimental Medicine·Laura SolforosiRoland C Zahn
Apr 19, 2021·Current Infectious Disease Reports·Arun KumarPaul A Kristiansen
Apr 7, 2021·JCI Insight·Jonathan L GolobAnna S Lok
May 1, 2021·Environmental Microbiology·Harald Brüssow
May 11, 2021·Nature·Kevin O SaundersBarton F Haynes
Jun 9, 2021·Scientific Reports·Luis Fernando Saraiva Macedo TimmersStefan Laufer
Jun 3, 2021·Nature Reviews. Microbiology·William T HarveyDavid L Robertson
Jun 3, 2021·Pathogens·Edyta JanikMichal Bijak
Jun 10, 2021·Signal Transduction and Targeted Therapy·Weilin Zhou, Wei Wang

Datasets Mentioned


Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.